Combination of oral temozolomide and etoposide as palliative chemotherapy for recurrent or progressive neuroblastoma

Pediatric Hematology and Oncology 2026

View at publisher
Authors: Katsutsugu Umeda, Satoshi Saida, Hirokazu Kobushi, Shuro Nishio, Ryo Akazawa, Hirohito Kubota, Itaru Kato, Miki L. Yamamoto, Elena Yukie Uebayashi, Eri Ogawa, Tatsuya Okamoto, Ikuya Usami
+4 more Daisuke Fukao, Kimiyoshi Sakaguchi, Hidefumi Hiramatsu, Junko Takita
DOI: 10.1080/08880018.2025.2586674
Cited by: 0
References: 19

Abstract

We retrospectively analyzed the clinical outcomes of seven patients receiving palliative treatment with oraltemozolomide (TMZ)/etoposide (ETP) for recurrent or progressive neuroblastoma (NB). Patients received a median of three cycles of TMZ/ETP. One patient achieved complete response (CR), three showed stable disease, and three showed progressive disease. The median time to progression in the six patients without achieving CR was 82 days excluding one achieving CR for >222 days. Grade 3 hematological toxicities were common but manageable, and no patients experienced severe non-hematological toxicity. TMZ/ETP is a feasible palliative chemotherapy option for certain patients with recurrent or progressive NB.

Fields of Study & Subjects

Neuroblastoma Research and Treatments Cancer therapeutics and mechanisms Lung Cancer Research Studies

Publication details

Journal / source
Pediatric Hematology and Oncology
Volume
43
Issue
1
Pages
54–62
Publication date
2 January 2026
Language
EN